Health min gets tough on pharma sector
Advertisement
In a move to implement stringent regulations in the pharmaceutical industry, the health ministry has initiated a broad survey of generic drugs for quality test purposes. This includes testing of over 42,000 samples of different therapeutic drugs drawn from various manufacturers.
“The survey is part of the quality assessment programme to increase the confidence levels for quality generic drugs manufactured in India and is expected to be completed in the next six to eight months,” GN Singh, drugs controller general (India), the ministry of health and family welfare, said.
“We faced a lot of challenges in the last two years coming from various issues and competition in the manufacturing process of generic drugs. Hence, we decided to strengthen the regulatory system in India with strong quality control measures,” Singh said, who was here on Tuesday to attend a workshop at the US Pharmacopeial Convention (USP), a body which establishes network to advance quality medicines. USP aims to advance the sustainable development of official medicines control laboratories (OMCLs) that are capable of producing and sharing harmonised and internationally-recognised data, ensuring the quality of medicines, and combatting the proliferation of falsified and substandard drugs.
“The survey is part of the quality assessment programme to increase the confidence levels for quality generic drugs manufactured in India and is expected to be completed in the next six to eight months,” GN Singh, drugs controller general (India), the ministry of health and family welfare, said.
“We faced a lot of challenges in the last two years coming from various issues and competition in the manufacturing process of generic drugs. Hence, we decided to strengthen the regulatory system in India with strong quality control measures,” Singh said, who was here on Tuesday to attend a workshop at the US Pharmacopeial Convention (USP), a body which establishes network to advance quality medicines. USP aims to advance the sustainable development of official medicines control laboratories (OMCLs) that are capable of producing and sharing harmonised and internationally-recognised data, ensuring the quality of medicines, and combatting the proliferation of falsified and substandard drugs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.